Peter Enzinger, MD
Enriched profileDirector, Center for Esophageal and Gastric Cancer; Institute Physician, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Peter Enzinger is Director, Center for Esophageal and Gastric Cancer; Institute Physician, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Peter Enzinger, DR, is Director, Center for Esophageal and Gastric Cancer at Dana-Farber Cancer Institute. The public record shows 280 publications with 26,688 citations (h-index 65), centered on Esophageal Neoplasms, Gastroesophageal Cancer, Stomach Neoplasms. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 24 companies.
- Top research focus: Esophageal Neoplasms
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Pembrolizumab in Refractory Advanced Esophageal Cancer
Sponsor: Dana-Farber Cancer Institute
- FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Sponsor: Dana-Farber Cancer Institute
- CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 15 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment$19,520openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Amgen Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
33.7%Phenothiazine19.4%Prochlorperazine Maleate100%Part D≥13 patientsOpioid Agonist14.3%Oxycodone Hcl100%Part D<11 patientsMetabolism & gastrointestinal
30.6%Serotonin-3 Receptor Antagonist16.3%Ondansetron Hcl100%Part D≥12 patientsOpioid Agonist14.3%Loperamide100%Part D<11 patientsSensory organs
23.5%Corticosteroid23.5%Dexamethasone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025 - Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/peter-enzinger-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Peter-C-Enzinger-39595004
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/issues/june-25-2016/expert-point-of-view-peter-c-enzinger-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Other
onclive.com/authors/peter-c-enzinger-md-dana-farber-cancer-institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
Brown University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Internal Medicine Residency
University of Rochester (Strong Memorial Hospital)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Medical Oncology and Hematology Fellowship
Memorial Sloan-Kettering Cancer Center (Cornell University)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Panel Member
NCCN Clinical Practice Guidelines in Oncology - Esophageal and Esophagogastric Junction Cancers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jnccn.org ↗ - Panel Member
NCCN Clinical Practice Guidelines in Oncology - Gastric Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jnccn.org ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH